DATE: February 6, 2000

SHEET \_1\_ of \_1\_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERC

(Modified)

PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

6587.US.O1

09/438,994

APPLICANT

S. L. Krill, et al. FILING DATE

GROUP

November 12 , 1999

1614

(37 CFR 1.98 (b))

## **U.S.PATENT DOCUMENTS**

EXAMINER									ISSUE			SUB	FILING
INJTIAL			PAT	EN	ΤN	UM	BEF	₹	DATE	PATENTEE	CLASS	CLASS	DATE
ALV	A1	5	8	8	9	0	5	1	03/30/99	Chen, et al.			
~													
					Г								

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

,	DOCUMENT NUMBER							ER	PUBLIC- ATION	COUNTRY OR		SUB	TRA LAT	
40		1							DATE	PATENT OFFICE	CLASS	CLASS	YES	NO
ASEX.	B1	0	8	5	2	1	4	0	08.07.98	EP				
AUX	B2	9	7	4	6	2	2	2	11.12.97	WO				
ALLA	B3	9	7	0	6	7	8	1	27.02.97	WO			Х	

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

AGR	C1	W. L. Chiou, et al., "Pharmaceutical Applications of Solid Dispersion Systems", JOURNAL OF PHARMACEUTICAL SCIENCES, 60 (9), (1971), 1281-1302.
AGR	C2	J. L. Ford, "The Current Status of Solid Dispersions", PHARM ACTA HELV, 61. Nr. 3, (1986) 69-88.
HEP	C3	B. J. Aungst, et al., "Improved Oral Bioavailability of an HIV Protease Inhibitor Using Celucire 44/14 and Labrasol Vehicles", B. T. GATTETOSSE, 87, (1994), 49-54.
AGA	C4	B. J. Aungst, et al., "Amphiphilic Vehicles Improve the Oral Bioavailability of a Poorly Soluble HIV Protease Inhibitor at High Doses", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 156 (1997), 79-88.

**EXAMINER** 

DATE CONSIDERED

7000

EXAMINER: Initial ditation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)